newsfilter
← Latest News
GlobeNewswire·

Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates

  • Xilio Therapeutics dosed the first patient in the Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific, in patients with metastatic NSCLC & expects to report initial Phase 1 data in Q4 2027.
  • The company is advancing XTX602 (dual-masked CLDN18.2-targeting TCE) & XTX701 (masked PSMAxSTEAP1-targeting TCE) toward planned IND applications in Q4 2027.
  • Xilio plans to deliver an option data package for efarindodekin alfa to Gilead Sciences in H1 2027.
  • Yariv Houvras, M.D., Ph.D., was appointed chief medical officer in September 2026.
  • Cash & cash equivalents were $122.2 million as of September 30, 2026, down from $137.5 million in December 2025.
  • Collaboration & license revenue totaled $10.0 million for Q3 2026, a decrease from $19.1 million in the same period last year.
  • Research & development expenses increased to $14.8 million in Q3 2026 from $14.3 million in Q3 2025, driven by preclinical TCE activities, XTX501 trial startup costs, & higher headcount.
  • General & administrative expenses rose to $6.9 million in Q3 2026 from $6.7 million in Q3 2025, primarily due to increased stock-based compensation.
  • The company reported a net loss of $5.9 million for Q3 2026, compared to a loss of $16.3 million in Q3 2025.
  • Xilio anticipates its current cash reserves will fund operations into Q1 2028, excluding potential proceeds from warrant exercises & contingent milestone payments.
Company
Xilio Therapeutics, Inc.
Keywords
Nasdaq:XLO, Xilio Therapeutics, Inc.